In a combined effort to help COVID-19 researchers the University of Oxford and Cardiff University have launched a series of \u201cliving reviews\u201d in Oxford University Press\u2019s new open access journal \u201cOxford Open Immunology\u201d.
Oxford University has today been awarded a \u00a32.4 million grant, as part of the Kennedy Trust MB PhD scheme, to fund undergraduate medical students to undertake DPhil research in the areas of inflammation, immunology and musculoskeletal disease.
New research from the Kusumbe Group at the Kennedy Institute has shown a direct correlation between age-related decline in capillary and artery numbers and hormone production in the endocrine system.
Five new Oxford-Bristol Myers Squibb Fellowships representing an investment of \u00a33M have been announced. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.
People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment that not only suppresses inflammation but also significantly reduces patient reported pain scores. Otilimab is a monoclonal antibody, biologic drug, which targets and suppresses the inflammatory cytokine GM-CSF.
An Oxford team from the Centre for Medicines Development, Department of Physiology Anatomy and Genetics and Radcliffe Department of Medicine led by Professor Jagdeep Nanchahal at the Kennedy Institute has been awarded a Wellcome Innovator Award to develop a first in class therapeutic aimed at regenerating heart muscle after heart attack.
Professor Gary Collins, Professor Cyrus Cooper, Professor Fiona Powrie and the late Professor Doug Altman have been named on the annual Highly Cited Researchers\u2122\ufe0f 2020 list from Clarivate.
In a collaboration with scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), Kennedy researchers have contributed to the discovery that neutrophils have many more functions in the body than previously thought. This finding suggests that neutrophil tissue-specific plasticity could be exploited in designing new treatments for neutrophil driven diseases, including cancer.
Professor Marco Fritzsche has joined the Kennedy Institute as the Principal Investigator of the Biophysical Immunology Laboratory (BPI), as part of a joint appointment with the Rosalind Franklin Institute. His lab is leading the development of a lattice light sheet microscope that will significantly advance the study of live cells.
A team from the University of Oxford has visualised how key cells of the immune system lock onto cancerous or infected cells to destroy them. The work was led by the Mike Dustin\u2019s group at the Kennedy Institute of Rheumatology and experts in colorectal and ovarian cancers from across Oxford and computational biologists at the University of Birmingham.
NDORMS researchers identify a subset of immune cells that could be a new therapeutic target to treat inflamed blood vessels in Giant Cell Arteritis (GCA) and other forms of inflammatory vascular disease.
Dr Rahul Ravindran has been awarded a highly competitive MRC Clinical Research Training Fellowship, following a successful research placement at the Kennedy Institute in 2019.
![\"Pile](\"https://www.kennedy.ox.ac.uk/news/immunology-preprint-reviews-launched-in-nature-reviews-immunology/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n